contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

a new North Karelia project?.. In my opinion, a good example of what NH’s method can aim for in Finland and similarly elsewhere in aging Western countries. The number of people needing care is increasing, the number of funders is decreasing, and treatments also seem to be getting more expensive. Often, the most cost-effective approach is preventative care, and I believe that more precise prescription of statins is just the tip of the iceberg. NH’s analytics improve the risk indicator and also provide precise information for improving different areas, in my view, more credibly than anything used before. It then remains to be seen how this translates into lifestyles, which I believe can have the greatest impact. Looking at the state of the national economy, where 7-9% (copilot) of the state budget is spent on “preventable” diseases/ailments, it would be almost mandatory to shift the focus from medical care to health maintenance. This is, of course, difficult when the citizen themselves is responsible, but all aids are welcome.

It’s quite small-scale for now, but I suppose that’s how it is when a new concept is introduced to a conservative industry—the first steps are small.

Press Release New wellbeing services county joins – North Karelia adopts disease risk identification as part of public healthcare 18.12.2025 at 15:00 Nightingale Health Nightingale Health Plc | Press Release | 18.12.2025 at 15:00:00 EET The North Karelia wellbeing services county pilots Nightingale Health’s blood analysis as part of health checks for the unemployed – the goal is a cost-effective and impactful preventive healthcare operating model. Nightingale Health’s goal is to develop a cost-effective and impactful healthcare operating model that helps target healthcare resources and strengthens preventive healthcare in the wellbeing services county. This pilot will accumulate valuable information on morbidity, changes in risks, and the effectiveness of interventions, supporting evidence-based decision-making. The health check for the unemployed is a statutory service intended to map and promote the health and wellbeing of an unemployed person and to support their work and functional capacity. The service is based on the Health Care Act and is aimed at individuals who are not covered by occupational or student healthcare. Nightingale Health’s technology is already in extensive use in the private sector, in the occupational health services of Terveystalo, Finland’s largest private healthcare provider. Nightingale Health announced earlier this autumn the expansion of its use in the private sector to all customer segments. Now, the use of the technology is expanding in public healthcare to a second wellbeing services county, the first being the previously announced South Savo wellbeing services county, further accelerating equitable and impactful preventive healthcare in Finland. “Nightingale’s technology offers a unique and cost-effective opportunity for identifying disease risks and targeting preventive measures at the population level. It is great that the North Karelia wellbeing services county is also joining to build an example of how preventive healthcare can be implemented extensively and impactfully as part of primary healthcare,” says Teemu Suna, CEO and Founder of Nightingale Health. “We need smarter ways to keep people healthy. With this pilot, as part of developing the health check process for the unemployed, we want to try earlier identification of disease risks and provide both healthcare professionals and individuals with clear and practical information about an individual’s health. Starting with health checks for the unemployed is logical – they are already part of statutory care and provide a natural platform for developing preventive services,” says Susanna Wilén, Director of Health and Wellbeing Services at the North Karelia wellbeing services county. The project will start immediately with a preparatory project, and the goal is to begin offering the Nightingale Health test as part of health checks for the unemployed in the first half of 2026. For more information, please contact: Teemu Suna, CEO

Inderes              Uusi tutkimus Nightingalen verianalyysin hyödyistä sydän- ja...    Uuden tutkimuksen mukaan yhtiön verianalyysi voi parantaa sydäninfarktien ja aivohalvausten riskintunnistusta.

Interpreted from the original publication with Copilot’s assistance: Traditional cholesterol measurements: LDL, HDL, triglycerides, sometimes ApoB and ApoA1, describe only a part of lipid metabolism. Reference values: are based on population-level studies. For example, LDL < 3 mmol/l is often considered “good,” but individual risk can still be elevated. For instance, LDL might be “normal,” but the number and quality of LDL particles (small, dense LDL particles) can still increase risk. HDL might be high, but its functional quality can be poor. Interpretation problem: values within the reference ranges do not always mean low risk, because the background of the risk is a complex overall picture of metabolism. Nightingale Health’s approach: NH does not only look at traditional cholesterol values but analyzes hundreds of biomarkers from a single blood sample. Broader profile: includes, for example, lipoprotein particle subtypes (different sizes and quantities of LDL and HDL), amino acids, fatty acids, inflammation markers, and energy metabolism metabolites. Risk identification: NH can identify individuals whose traditional values are “normal,” but whose metabolic profile indicates an elevated risk. For example, the ApoB/ApoA1 ratio and LDL particle subtypes can reveal a risk that a mere LDL value does not show.

Various cholesterols are already measured with “normal” blood tests, and cholesterol-lowering treatment is given as needed. Are the reference values too high, or is it that not all risk can be inferred from normal blood test values, even if they are within the limits? A few years ago, I had an NH test at Terveystalo. My cholesterol balance was “average”, and going into details, there were some Apo values, as well as total, LDL, HDL, and VLDL cholesterols, and triglycerides. Can NH find more risk cases or similar from those values and their ratios than other medicine?

Press Release Significant Study: Nightingale Health’s Blood Analysis Helps Prevent 44% More Heart Attacks and Strokes Compared to Current Healthcare Practice December 17, 2025 Nightingale Health Nightingale Health Plc | Press Release | December 17, 2025 at 09:30:00 EET An independent study shows that Nightingale Health’s blood analysis can improve the prevention of heart attacks and strokes by 44% when used in population-level health screenings. The test identifies high-risk individuals not detected by current tools used for identifying disease risks. The study was conducted by world-leading cardiovascular researchers from the University of Cambridge and published in the prestigious main journal of the European Society of Cardiology (European Heart Journal). The study result is based on data from approximately 300,000 middle-aged Britons, which was modeled to assess the impact of adding Nightingale Health’s test to SCORE2, a cardiovascular disease risk calculator commonly used in Europe. Better prevention with Nightingale Health’s test is possible because the blood values analyzed by Nightingale Health more accurately identify individuals who should be recommended cholesterol-lowering treatment. The study states that this improvement would not increase the number of individuals treated per prevented heart attack. “One of the key findings of our study is that adding metabolomics to current cardiovascular health screening could bring significant population-level health benefits if applied widely,” says Professor Michael Inouye, principal investigator of the study from the Cardiovascular Epidemiology Unit at Cambridge. Nightingale Health’s blood analysis is a clinical tool that is scalable for the entire population and has been approved for healthcare use in the European Union, the United Kingdom, Japan, and Singapore. In Finland, the blood analysis is used in national healthcare, and over 200,000 people have already received their test results. In addition to cardiovascular disease risk, Nightingale Health’s technology simultaneously identifies the risk of type 2 diabetes, chronic kidney disease, and fatty liver with a single test, and with comparable or better performance than current healthcare tools used for identifying disease risks. “This study provides extensive evidence that Nightingale Health’s blood analysis can fundamentally improve the prevention of cardiovascular diseases. A 44% improvement in preventing heart attacks and strokes is a significant leap towards a healthier population. Importantly, this groundbreaking result can be achieved by using conventional cholesterol-lowering treatment, prescribing it to those who need it most. The study shows that Nightingale Health’s blood analysis is superior in finding precisely these individuals in a scalable way,” says Teemu Suna, CEO and Founder of Nightingale Health. “For healthcare systems, this means the opportunity to prevent more heart attacks and strokes without increasing the number of treated individuals per prevented heart attack. For doctors, it means having a scalable, evidence-based tool available that reveals hidden risk in patients who appear healthy based on current risk identification methods. For patients, it means a more effective and simpler way to avoid heart attacks and strokes. We are proud to help healthcare systems in Europe and around the world take a big step towards more efficient, proactive, and cost-effective healthcare,” Teemu Suna continues.

Nightingale Health

Nightingale's investment story is at a potential turning point. The company’s two large-scale customers (Terveystalo & Pathology Asia) seem to be progressing promisingly. Nightingale’s commercial strategy may be gaining clear proof of its functionality this year in the form of revenue growth and new customer gains.

<p>Nightingale's investment story is at a potential turning point. The company’s two large-scale customers (Terveystalo &amp; Pathology Asia) seem to be progressing promisingly. Nightingale’s commercial strategy may be gaining clear proof of its functionality this year in the form of revenue growth and new customer gains. The risk level remains very high due to poor visibility, but with the current valuation and the stronger growth outlook, we consider the risk/reward ratio to be sufficiently attractive. </p> 

	2023	24e	25e
Revenue	4.2	4.7	8.7
growth-%	80.8 %	12.8 %	85.0 %
EBIT (adj.)	-18.5	-17.8	-17.6
EBIT-% (adj.)	-442.9 %	-377.5 %	-201.9 %
EPS (adj.)	-0.30	-0.27	-0.27
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	0.8	neg.	neg.

Nightingale Health: Spring is in the air

Key Estimate Figures2024-03-08

Forum discussions